Respiratory Distress Syndrome – Pipeline Review, H1 2012
Respiratory Distress Syndrome – Pipeline Review, H1
2012
Reference Code: GMDHC1702IDB
Publication Date: January 2012
Respiratory Distress Syndrome – Pipeline Review, H1 2012 GMDHC1702IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Respiratory Distress Syndrome – Pipeline Review, H1 2012
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables ................................................................................................................................................................................. 6
List of Figures ................................................................................................................................................................................ 7
Introduction......................................................................................................................................................................................... 8
Global Markets Direct Report Coverage ........................................................................................................................................ 8
Respiratory Distress Syndrome Overview .......................................................................................................................................... 9
Therapeutics Development............................................................................................................................................................... 10
An Overview of Pipeline Products for Respiratory Distress Syndrome ........................................................................................ 10
Respiratory Distress Syndrome Therapeutics under Development by Companies .......................................................................... 12
Respiratory Distress Syndrome Therapeutics under Investigation by Universities/Institutes............................................................ 14
Late Stage Products ......................................................................................................................................................................... 16
Comparative Analysis .................................................................................................................................................................. 16
Mid Clinical Stage Products.............................................................................................................................................................. 17
Comparative Analysis .................................................................................................................................................................. 17
Early Clinical Stage Products ........................................................................................................................................................... 18
Comparative Analysis .................................................................................................................................................................. 18
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 19
Comparative Analysis .................................................................................................................................................................. 19
Respiratory Distress Syndrome Therapeutics – Products under Development by Companies ........................................................ 20
Respiratory Distress Syndrome Therapeutics – Products under Investigation by Universities/Institutes ......................................... 21
Companies Involved in Respiratory Distress Syndrome Therapeutics Development ....................................................................... 22
United Therapeutics Corporation ................................................................................................................................................. 22
GlaxoSmithKline plc .................................................................................................................................................................... 23
Discovery Laboratories, Inc. ........................................................................................................................................................ 24
Pacgen Biopharmaceuticals Corporation .................................................................................................................................... 25
Advanced Life Sciences Holdings, Inc......................................................................................................................................... 26
Altor BioScience Corporation....................................................................................................................................................... 27
NovImmune SA ........................................................................................................................................................................... 28
Ikaria Inc. ..................................................................................................................................................................................... 29
Kemin Industries, Inc. .................................................................................................................................................................. 30
Faron Pharmaceuticals, Ltd. ........................................................................................................................................................ 31
Respiratory Distress Syndrome – Therapeutics Assessment ........................................................................................................... 32
Assessment by Monotherapy Products ....................................................................................................................................... 32
Assessment by Combination Products ........................................................................................................................................ 33
Assessment by Route of Administration ...................................................................................................................................... 34
Assessment by Molecule Type .................................................................................................................................................... 36
Drug Profiles..................................................................................................................................................................................... 39
Aviptadil - Drug Profile ................................................................................................................................................................. 39
Product Description................................................................................................................................................................. 39
Mechanism of Action ............................................................................................................................................................... 39
R&D Progress ......................................................................................................................................................................... 39
ALS-886 - Drug Profile ................................................................................................................................................................ 41
Respiratory Distress Syndrome – Pipeline Review, H1 2012 GMDHC1702IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Respiratory Distress Syndrome – Pipeline Review, H1 2012
Product Description................................................................................................................................................................. 41
Mechanism of Action ............................................................................................................................................................... 41
R&D Progress ......................................................................................................................................................................... 41
NI-0101 - Drug Profile.................................................................................................................................................................. 42
Product Description................................................................................................................................................................. 42
Mechanism of Action ............................................................................................................................................................... 42
R&D Progress ......................................................................................................................................................................... 42
SB681323 - Drug Profile .............................................................................................................................................................. 43
Product Description................................................................................................................................................................. 43
Mechanism of Action ............................................................................................................................................................... 43
R&D Progress ......................................................................................................................................................................... 43
Aerosurf - Drug Profile ................................................................................................................................................................. 45
Product Description................................................................................................................................................................. 45
Mechanism of Action ............................................................................................................................................................... 45
R&D Progress ......................................................................................................................................................................... 45
Surfaxin - Drug Profile ................................................................................................................................................................. 47
Product Description................................................................................................................................................................. 47
Mechanism of Action ............................................................................................................................................................... 47
R&D Progress ......................................................................................................................................................................... 47
PAC-G31P - Drug Profile ............................................................................................................................................................. 49
Product Description................................................................................................................................................................. 49
Mechanism of Action ............................................................................................................................................................... 49
R&D Progress ......................................................................................................................................................................... 49
ALT-836 - Drug Profile ................................................................................................................................................................. 50
Product Description................................................................................................................................................................. 50
Mechanism of Action ............................................................................................................................................................... 50
R&D Progress ......................................................................................................................................................................... 50
APN01 - Drug Profile ................................................................................................................................................................... 52
Product Description................................................................................................................................................................. 52
Mechanism of Action ............................................................................................................................................................... 52
R&D Progress ......................................................................................................................................................................... 52
KPE00001175 - Drug Profile ............................................................................................................................................